Since MKK6 activates p38 through phosphorylation, we selected the p38 inhibitor SB203580 to determine its effects on reducing RPS15 expression in order to test the role of p38 MAPKs in the malignant phenotype of ESCC. The gene discussed is MAP2K6; the disease is esophageal squamous cell carcinoma.